Douglas Carr - 02 Feb 2026 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Reporting relationship: SVP Finance & Operations
Issuer ticker: IPSC
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:12:06 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Douglas Carr

Key filing fact

Douglas Carr filed Form 4 for Century Therapeutics, Inc. (IPSC) on 04 Feb 2026.

Key facts

This page summarizes Douglas Carr's Form 4 filing for Century Therapeutics, Inc. (IPSC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:12.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867173 Primary reporting owner

Carr Douglas

Relationship: SVP Finance & Operations
Address: C/O CENTURY THERAPEUTICS, INC., 25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Signature: /s/ Douglas Carr
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IPSC transaction

Common Stock

Award

Transaction value: $0
Shares: +110,000
Change %: +27%
Price: $0.000000
Shares after: 514,874
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IPSC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +225,000
Change %
Price: $0.000000
Shares after: 225,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,000
Exercise price: $1.84
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Footnote F2

The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.